Nevolat (Liraglutide)

Liraglutide binds to and activates the GLP‑1 receptor, which enhances glucose‑dependent insulin secretion, suppresses inappropriate glucagon release, slows gastric emptying, and promotes satiety. These combined actions lower blood glucose levels and support weight loss.

The dose of Nevolat is individualized by the prescribing healthcare professional. Initiation typically starts at a low dose that is gradually increased based on therapeutic response and tolerability, following the prescriber’s clinical judgment.

Safety data for liraglutide in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order Nevolat, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and required import documentation.

Nevolat (liraglutide) shares the core GLP‑1 receptor activation mechanism with other agents in its class, but differences exist in dosing frequency, molecular structure, and clinical trial outcomes. Liraglutide is administered once daily, whereas some alternatives are weekly, and it has demonstrated cardiovascular benefit in specific patient populations.

Nevolat must be stored in a refrigerator at 2‑8 °C, protected from light, and must not be frozen or shaken. If temporary storage at controlled room temperature is unavoidable, it should not exceed 30 °C for more than 14 days, after which any remaining product should be discarded.

Nevolat is supplied as a sterile solution for subcutaneous injection. It is injected into the abdomen, thigh, or upper arm using a pre‑filled pen or syringe, following the injection technique and site‑rotation guidelines provided by the prescribing clinician.

Serious risks include pancreatitis, severe hypoglycemia (especially when combined with insulin or sulfonylureas), gallbladder disease, acute renal impairment, and rare allergic reactions such as anaphylaxis. Patients should be educated to seek immediate medical attention if they experience persistent abdominal pain, vomiting, or signs of an allergic response.

Nevolat is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma, those with multiple endocrine neoplasia type 2 (MEN 2), or patients who have experienced a severe hypersensitivity reaction to liraglutide or any of its excipients.